Aptuit to buy Quintiles units in $125M deal

Aptuit has struck a deal to acquire three Quintiles Transnational business units for $125 million, the two companies announced. The units, which now employ 1,400 and provide services to 19 of the world's 20 largest drug companies, are key to Aptuit's strategy of building a comprehensive drug-development services company. Aptuit intends to reorganize the units and to invest $50 million in developing them over the next several years but says the transition will be "virtually seamless" to employees and customers. The deal also includes a multi-year joint-marketing deal between the two companies.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.